Enasidenib in combination with azacitadine, compared with azacitadine alone, has also been studied in a phase 1b/2 trial in adults with newly diagnosed IDH2-mutant AML; in the phase 2 portion, there was an ORR of 74% for patients in the combination group versus 36% for patients in the azacitadine monotherapy group [87]. This evidence concerns the gene IDH2 and acute myeloid leukemia.